$24.20
0.37% yesterday
NYSE, Aug 12, 10:10 pm CET
ISIN
US3580291066
Symbol
FMS

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock price

$24.20
-2.95 10.87% 1M
-0.12 0.49% 6M
+1.56 6.89% YTD
+6.07 33.48% 1Y
+5.32 28.18% 3Y
-19.20 44.24% 5Y
-16.84 41.03% 10Y
+16.73 223.96% 20Y
NYSE, Closing price Tue, Aug 12 2025
+0.09 0.37%

Key metrics

Basic
Market capitalization
$14.0b
Enterprise Value
$24.3b
Net debt
$10.3b
Cash
$2.6b
Shares outstanding
293.4m
Valuation (TTM | estimate)
P/E
9.3 | 5.6
P/S
0.6 | 0.6
EV/Sales
1.1 | 1.1
EV/FCF
10.4
P/B
0.9
Dividends
DPS
$0.81
Yield 1Y | 5Y
3.4% | 2.8%
Growth 1Y | 5Y
26.8% | 2.6%
Payout 1Y | 3Y
30.2% | 28.9%
Increased
2 Years
Financials (TTM | estimate)
Revenue
$22.8b | $23.0b
EBITDA
$3.5b | $4.2b
EBIT
$1.6b | $2.4b
Net Income
$766.4m | $1.3b
Free Cash Flow
$2.4b
Growth (TTM | estimate)
Revenue
0.5% | 2.4%
EBITDA
-4.1% | 21.6%
EBIT
2.7% | 66.1%
Net Income
23.8% | 102.1%
Free Cash Flow
50.2%
Margin (TTM | estimate)
Gross
24.7%
EBITDA
15.4% | 18.5%
EBIT
7.2%
Net
3.4% | 5.5%
Free Cash Flow
10.3%
Financial Health
Equity Ratio
43.4%
Return on Equity
3.7%
ROCE
5.4%
ROIC
4.1%
Debt/Equity
0.8
More
EPS
$2.6
FCF per Share
$8.0
Short interest
0.2%
Employees
112k
Rev per Employee
$200.0k
Show more

Is Fresenius Medical Care AG & Co. KGaA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

9x Buy
36%
12x Hold
48%
4x Sell
16%

Analyst Opinions

25 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

Buy
36%
Hold
48%
Sell
16%

Financial data from Fresenius Medical Care AG & Co. KGaA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
22,788 22,788
1% 1%
100%
- Direct Costs 17,166 17,166
1% 1%
75%
5,621 5,621
2% 2%
25%
- Selling and Administrative Expenses 3,664 3,664
1% 1%
16%
- Research and Development Expense 200 200
19% 19%
1%
3,512 3,512
4% 4%
15%
- Depreciation and Amortization 1,883 1,883
9% 9%
8%
EBIT (Operating Income) EBIT 1,629 1,629
3% 3%
7%
Net Profit 766 766
24% 24%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Fresenius Medical Care AG & Co. KGaA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Neutral
PRNewsWire
one day ago
Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which i...
Neutral
Seeking Alpha
7 days ago
Fresenius Medical Care AG (NYSE:FMS ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Ca...
Neutral
PRNewsWire
8 days ago
Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed to earnings Operating income2 grew by 13% at constant currency, further driving margin expansion Stable reported operating income and 20% increase in reported net income3 Operating cash flow improve...
More Fresenius Medical Care AG & Co. KGaA Sponsored ADR News

Company Profile

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Head office Germany
CEO Helen Giza
Employees 111,513
Founded 1996
Website www.freseniusmedicalcare.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today